Life-sciences
1.4K views | +0 today
Follow
Life-sciences
Your new post is loading...
Your new post is loading...
Scooped by Christopher Rudolf
Scoop.it!

Learning a rare disease without labels

Learning a rare disease without labels | Life-sciences | Scoop.it

Thanks to all the team for making the World #AICongress such a success this week.

https://theaicongress.com/

 

We had kept the lid on the fact that we had built a #machinelearning methodology that was based on #zerolabelleddata to become more accurate in #diagnosis of a complex and #ultrarare disease than specialist physicians. Yes, you read that right.
It was pretty cool and lots of questions....

 

However, as humans we make these #suppositional leaps all the time.

 

What is really interesting though, is that we can now learn all of the top rare diseases, find their true prevalence, and then also find the patients at a level well above current #state-of-the-art.

 

So thanks to all who joined us on this journey, and we look forward to chatting with anyone interested.

 

We are just about to build models for ... watch this space.
#volvglobal

Christopher Rudolf's insight:

Thanks to all the team for making the World #AICongress such a success this week.

https://theaicongress.com/

We had kept the lid on the fact that we had built a #machinelearning methodology that was based on #zerolabelleddata to become more accurate in #diagnosis of a complex and #ultrarare disease than specialist physicians. Yes, you read that right.
It was pretty cool and lots of questions....

However, as humans we make these #suppositional leaps all the time.

What is really interesting though, is that we can now learn all of the top rare diseases, find their true prevalence, and then also find the patients at a level well above current #state-of-the-art.

So thanks to all who joined us on this journey, and we look forward to chatting with anyone interested.

We are just about to build models for ... watch this space.
#volvglobal

more...
No comment yet.
Rescooped by Christopher Rudolf from Life-sciences
Scoop.it!

ANNUAL ARTIFICIAL INTELLIGENCE IN PHARMA INDUSTRY SUMMIT – Curtis & Wyss | Healthcare

ANNUAL ARTIFICIAL INTELLIGENCE IN PHARMA INDUSTRY SUMMIT – Curtis & Wyss | Healthcare | Life-sciences | Scoop.it

Curtis & Wyss Group is pleased to invite you to the Artificial Intelligence in Pharma Industry Summit scheduled for February 19 – 20, 2018 in Berlin.

This premier B2B event will bring together experts from all levels of the of the value chain to ensure maximum knowledge transfer and professional exchange; elaborate on the best practices within the companion industry, hear and learn about their experiences on latest trends on companion development, to network and enjoy excellent mix of case studies, interactive panel discussions, speed networking and workshops.

It is an honor and privilege to invite you to participate in this Summit.

We look forward to welcoming you at the Summit in Germany upcoming February!

Christopher Rudolf's insight:

Volv has been invited to speak at the Artificial Intelligence in Pharma Industry Summit Berlin February 19/20

Come and see us there, we are looking forward to a great event.

We are covering:

1. AI : Exceeding human performance & creating value in Pharma now – a Case Study

  • How to plan for personalised medicine & rare diseases through combination methodologies
    • Learning a disease
    • Learning features that identify patients with difficult to diagnose diseases
    • Finding cohorts for specialists using anonymised data
    • Creating value & ROI

 

2. Predicting success and changing the nature of your R&D investment – solving 4 key problems to deliver predictive value

  • Identifying scientific research of good quality
  • Short listing tech transfer candidates
  • Finding Candidate likely to have success in Clinical Trials
  • Predicting candidate likely to get FDA approval
more...
Christopher Rudolf's curator insight, January 18, 8:23 PM

Volv has been invited to speak at the Artificial Intelligence in Pharma Industry Summit Berlin February 19/20

Come and see us there, we are looking forward to a great event.

We are covering:

1. AI : Exceeding human performance & creating value in Pharma now – a Case Study

  • How to plan for personalised medicine & rare diseases through combination methodologies
    • Learning a disease
    • Learning features that identify patients with difficult to diagnose diseases
    • Finding cohorts for specialists using anonymised data
    • Creating value & ROI

 

2. Predicting success and changing the nature of your R&D investment – solving 4 key problems to deliver predictive value

  • Identifying scientific research of good quality
  • Short listing tech transfer candidates
  • Finding Candidate likely to have success in Clinical Trials
  • Predicting candidate likely to get FDA approval
Rescooped by Christopher Rudolf from Life-sciences
Scoop.it!

Volv Global At Clinical Trials Connect 2018

Volv Global At Clinical Trials Connect 2018 | Life-sciences | Scoop.it

Come and Join us in April at the Global Clinical Trials Connect Conference

Volv will be at the conference talking about how it is seeing a real shift in what is possible and what is being adopted to keep the industry competitive while remaining steadfastly patient focussed. We will try to show how an AI-enabled biopharma company (or CROs) can now
1. recruit biomarker-qualified patients for trials, in a new way using
  - predictive cognitive markers,
  - digital biomarkers and
  - biomarkers
2. select patients for approved precision treatments with accuracy unachievable until now and then
3. track outcomes to enhance future selection
and finally why this is a now a reality, and indeed a real opportunity.

more...
Christopher Rudolf's curator insight, January 18, 7:53 AM

Looking forward to speaking to such an experienced audience at the Global Clinical Trials Connect conference, London April 2018

Scooped by Christopher Rudolf
Scoop.it!

The AI Congress London - insight into the impact of Artificial Intelligence on businesses

The AI Congress London - insight into the impact of Artificial Intelligence on businesses | Life-sciences | Scoop.it

The AI World Congress will provide an innovative forum to discuss, engage,
challenge and discover the incredible opportunities in AI. The AI World
Congress is a leading and large-scale global event taking place at the
iconic and world famous O2.

Christopher Rudolf's insight:

Come and se us at the World AI Congress Jan 30/31 at the O2, London
Volv Global is proud to be a Gold Sponsor there.

 

We will be talking about how we can enable engagement with small populations for Rare Diseases & Personalised Medicines, how we can help identify patients earlier and the top line impact for customers in terms of market access and physician and patient engagement.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

PLG inVolv Launch with sound

PLG inVolv Launch with sound. ProductLife Group Adds Innovative Social Media Listening Capabilities to Pharmacovigilance Solution Suite via Strategi
Christopher Rudolf's insight:

Come and look at our intro video that we showed at DIA Europe. 2 more products in the pipeline that will make you wonder. The Future is Today, with volv partners.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

AI is the Next-Generation Response to the Current Phenomenon of Social Listening - ProductLife Group

AI is the Next-Generation Response to the Current Phenomenon of Social Listening - ProductLife Group | Life-sciences | Scoop.it
Patient forums on social media are growing exponentially. How a drug is used, why a patient has stopped taking it, how an individual’s friends or relatives reacted to a drug are all commonly shared across these channels. In a recent PharmaVOICE article, I spoke about how social media is disrupting the traditional definition of “case”
Christopher Rudolf's insight:

Been a pleasure to work with Marco and the team recently, and this is a great article worth reading...

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Data Selfie

Data Selfie | Life-sciences | Scoop.it

It’s a Chrome extension "that tracks you while you are on Facebook to show you your own data traces and reveal how machine learning algorithms use your data to gain insights about your personality. The tool explores our relationship to the online data we leave behind as a result of media consumption and social networks - the information you share consciously and unconsciously."

Christopher Rudolf's insight:

As we share more, is it right that others commercialise? There is a new trajectory, we believe, that is really relevant in life sciences and healthcare, where own the data you share. You are the platform... Data Selfie is another great tool to help you understand your sharing impact. 
As we design  more tools for the Digital Self, RWE, ePRO etc, we need to be mndful of the new paradigm. At Volv we work with technology partners that understand this new digital world.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Global prescription drug spend seen at $1.5 trillion in 2021 - report

Global prescription drug spend seen at $1.5 trillion in 2021 - report | Life-sciences | Scoop.it
Global spending on prescription medicines will reach nearly $1.5 trillion by 2021, although the annual rate of growth will decrease from recent years, according to a forecast by Quintiles IMS Holding (Q.N) released on Tuesday.
Christopher Rudolf's insight:

This is a shockingly large number. Is it affordable?

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

HEALTH | mPower

HEALTH | mPower | Life-sciences | Scoop.it
Christopher Rudolf's insight:

Again connecting the more difficult regions and people mPower. Focus on the most marginalised and you could disrupt the less marginalised.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Partially-sighted Paralympian gets to see boyfriend clearly - BBC News

Partially-sighted Paralympian gets to see boyfriend clearly - BBC News | Life-sciences | Scoop.it
Partially-sighted Paralympian Libby Clegg gets to see her boyfriend's face more clearly thanks to hi-tech goggles.
Christopher Rudolf's insight:

Another example of consumer products making a meaningful difference ....

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

'Corporate innovation does not work,' says Accenture

'Corporate innovation does not work,' says Accenture | Life-sciences | Scoop.it
Accenture's Narry Singh tells WIRED2016 that startups and corporates should collaborate for the best results
Christopher Rudolf's insight:

I must say I could not agree more, that is precisely the reason that I have started Volv with my partners.  

 

I was constantly finding that colleagues and teams were hampered by middle management's lack of understanding of new ideas and how they could contribute to overall business transformation and growth.

 

Fundamentally, large organisations are filled with people that are exhibiting sustaining and in many cases even blocking behaviors and not accelerating behaviors required for innovation. 

 

In my view it is a behavioral issue driven by collective corporate culture. Teaming and partnering is a way to bring innovation in, but the temptation is then to 'buy' that talent. That is often a disaster in waiting: trying to then fit the round innovative peg into the square corporate hole.

 

How many times do we see rapid exit of talent unless golden hand-cuffs are applied? 

 

Partner platforms are the way forward.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Simple Digital Technologies Can Reduce Health Care Costs

Diabetes and hypertension are among the chronic diseases where tech can help.
Christopher Rudolf's insight:

We actually see that the digital simplification and scale model can work particularly well in emerging economies.


 


Agree with the main tenets in this article, some key areas to consider are:


 


Who's data is it?


How are we protecting it?


How do we allow the customers the right to be forgotten?


 


In the race to integrated value in healthcare, we predict that companies are exposing themselves to future risk, even though improved outcomes are the imperative.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Google Deepmind: Should patients trust the company with their data? - BBC News

Google Deepmind: Should patients trust the company with their data? - BBC News | Life-sciences | Scoop.it
Google has ambitious plans for using medical records and appears to also be bidding to create a truly digitised NHS.
Christopher Rudolf's insight:

Well I would also tend to have reservations as suggested in this article. Especially since as previously posted, there are issues with potential prejudice in AI algorithms, plus the unknown artefact issue. Scope boundary would be an important area to understand better.

And: why Google? Why not other AI, there are other options out there many of them budding within universities.

After many years of often stalled efforts to try to get simple efficiencies into the NHS in this area, there seems now to be a headlong rush. Just my thoughts. 

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Volv Global to Enter into New Strategic Partnership

Volv Global to Enter into New Strategic Partnership | Life-sciences | Scoop.it

Volv Global will announce a new major strategic partnership giving access to patient records across Europe at the World AI Congress on January 30/31, 2018 at the O2 London . . .

Christopher Rudolf's insight:

I am really very excited to be able to announce this partnership very soon indeed. It will be a major step forward in enabling personalised medicine and treatments for rare diseases to be delivered at a better price point in the future, as we make it easier for our customers to enter these challenging markets.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

ANNUAL ARTIFICIAL INTELLIGENCE IN PHARMA INDUSTRY SUMMIT – Curtis & Wyss | Healthcare

ANNUAL ARTIFICIAL INTELLIGENCE IN PHARMA INDUSTRY SUMMIT – Curtis & Wyss | Healthcare | Life-sciences | Scoop.it

Curtis & Wyss Group is pleased to invite you to the Artificial Intelligence in Pharma Industry Summit scheduled for February 19 – 20, 2018 in Berlin.

This premier B2B event will bring together experts from all levels of the of the value chain to ensure maximum knowledge transfer and professional exchange; elaborate on the best practices within the companion industry, hear and learn about their experiences on latest trends on companion development, to network and enjoy excellent mix of case studies, interactive panel discussions, speed networking and workshops.

It is an honor and privilege to invite you to participate in this Summit.

We look forward to welcoming you at the Summit in Germany upcoming February!

Christopher Rudolf's insight:

Volv has been invited to speak at the Artificial Intelligence in Pharma Industry Summit Berlin February 19/20

Come and see us there, we are looking forward to a great event.

We are covering:

1. AI : Exceeding human performance & creating value in Pharma now – a Case Study

  • How to plan for personalised medicine & rare diseases through combination methodologies
    • Learning a disease
    • Learning features that identify patients with difficult to diagnose diseases
    • Finding cohorts for specialists using anonymised data
    • Creating value & ROI

 

2. Predicting success and changing the nature of your R&D investment – solving 4 key problems to deliver predictive value

  • Identifying scientific research of good quality
  • Short listing tech transfer candidates
  • Finding Candidate likely to have success in Clinical Trials
  • Predicting candidate likely to get FDA approval
more...
Christopher Rudolf's curator insight, January 18, 8:25 PM

Volv has been invited to speak at the Artificial Intelligence in Pharma Industry Summit Berlin February 19/20

Come and see us there, we are looking forward to a great event.

We are covering:

1. AI : Exceeding human performance & creating value in Pharma now – a Case Study

  • How to plan for personalised medicine & rare diseases through combination methodologies
    • Learning a disease
    • Learning features that identify patients with difficult to diagnose diseases
    • Finding cohorts for specialists using anonymised data
    • Creating value & ROI

 

2. Predicting success and changing the nature of your R&D investment – solving 4 key problems to deliver predictive value

  • Identifying scientific research of good quality
  • Short listing tech transfer candidates
  • Finding Candidate likely to have success in Clinical Trials
  • Predicting candidate likely to get FDA approval
Scooped by Christopher Rudolf
Scoop.it!

Volv Global At Clinical Trials Connect 2018

Volv Global At Clinical Trials Connect 2018 | Life-sciences | Scoop.it

Come and Join us in April at the Global Clinical Trials Connect Conference

Volv will be at the conference talking about how it is seeing a real shift in what is possible and what is being adopted to keep the industry competitive while remaining steadfastly patient focussed. We will try to show how an AI-enabled biopharma company (or CROs) can now
1. recruit biomarker-qualified patients for trials, in a new way using
  - predictive cognitive markers,
  - digital biomarkers and
  - biomarkers
2. select patients for approved precision treatments with accuracy unachievable until now and then
3. track outcomes to enhance future selection
and finally why this is a now a reality, and indeed a real opportunity.

Christopher Rudolf's insight:

Looking forward to speaking to such an experienced audience at the Global Clinical Trials Connect conference, London April 2018

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Americans Demand Lower Drug Prices: This Senate Bill Would Deliver

Americans Demand Lower Drug Prices: This Senate Bill Would Deliver | Life-sciences | Scoop.it
It is morally wrong that in the richest country in the world, at the richest point in our history, millions of Americans don’t take the medicines thei
more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

The rise of the machines: Algorithmic possibilities in life sciences

The rise of the machines: Algorithmic possibilities in life sciences | Life-sciences | Scoop.it

The rise of the machines: Algorithmic possibilities in life sciences | Adam Sherlock | Pulse | LinkedIn

The availability of the first real, commercial, solutions using practically applied Artificial Intelligence (AI) appears to have really caught the imaginations of industry

 

Christopher Rudolf's insight:

The rise of the machines: Algorithmic possibilities in life sciences | Adam Sherlock | Pulse | LinkedIn

The availability of the first real, commercial, solutions using practically applied Artificial Intelligence (AI) appears to have really caught the imaginations of industry

 

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

How Artificial Intelligence Can Help PV Become a Competitive Advantage - ProductLife Group

How Artificial Intelligence Can Help PV Become a Competitive Advantage - ProductLife Group | Life-sciences | Scoop.it
The tide is turning at pharmaceutical companies as a growing number recognise that pharmacovigilance can be a competitive advantage. While there is still a long way to go, many industry leaders are looking to take a more proactive approach to the vast expanse of patient reported data, clinical data, and real-world outcomes that exists in
Christopher Rudolf's insight:

How Artificial Intelligence Can Help PV Become a Competitive Advantage - ProductLife Group http://sco.lt/...

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

This New Patch Can Monitor Patient's Vital Signs With High Accuracy

This New Patch Can Monitor Patient's Vital Signs With High Accuracy | Life-sciences | Scoop.it
A new patch from VitalConnect that can monitor a patient's vital signs could replace unwieldy wired monitoring equipment.
Christopher Rudolf's insight:

We are really pleased to be associated with partners MediBioSense who have been working on this. If you want to talk to us about how we can help secure the patient data, let us know.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

RapidPro - Visually build interactive SMS Applications

RapidPro - Visually build interactive SMS Applications | Life-sciences | Scoop.it
RapidPro lets you visually build interactive SMS applications and launch them anywhere in the world.
Christopher Rudolf's insight:

And now thinking about those that have access to at least SMS this is a great opensource framework for engaging meaningfully with those communities....

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

SayCel

SayCel | Life-sciences | Scoop.it
Find investment information and connect with SayCel, a Corn Island, Nicaragua based Telecommunications startup.
Christopher Rudolf's insight:

We can often forget about the digitally disadvantaged and dis-empowered,  SayCel is worth looking at because they are closing that loop...

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

Australian Teens Recreate Key Ingredient in 'Pharma Bro' Drug for Just $20

Australian Teens Recreate Key Ingredient in 'Pharma Bro' Drug for Just $20 | Life-sciences | Scoop.it
High schoolers take down Martin Shkreli.
Christopher Rudolf's insight:

School kids are the solution to healthcare costs! Fantastic Story . . .

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

volv partners

volv partners | Life-sciences | Scoop.it
Volv Partners' mission is to speed science, reduce cost of healthcare, revolutionise finance thereby enhancing the economic output and well-being for all.
Christopher Rudolf's insight:

Volv Partners are getting up to speed, look for some strategic partnership announcements soon.

more...
No comment yet.
Scooped by Christopher Rudolf
Scoop.it!

How cloud computing can transform the pharmaceutical industry

How cloud computing can transform the pharmaceutical industry | Life-sciences | Scoop.it
  As you know, a number of significant trends have shaped the pharmaceutical ecosystem over the last few years. The increasing need to develop personalised medicines has added to the complexity of care. A flurry of mergers and acquisitions have created huge, competing conglomerates. And stringent regulation and tighter price controls have forced many firms
more...
No comment yet.